A Randomized Phase II study of TYRA-300 in patients with pediatric achondroplasia
Latest Information Update: 03 Jul 2024
At a glance
- Drugs TYRA-300 (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 02 Jul 2024 According to a Tyra Biosciences media release, company is looking forward to submit IND in the second half of this year to support our planned Phase 2 study in pediatric achondroplasia.
- 01 Feb 2024 According to a Tyra Biosciences media release, company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300 for the treatment of achondroplasia.
- 22 Dec 2023 According to a Tyra Biosciences media release, the company has received feed back from FDA and plans to submit an Investigational New Drug (IND) application to the US FDA in the second half of 2024 for the initiation of the Phase 2 study.